Monday, October 13, 2008
Bioprin Featured By Whole Dog Journal
Recently, JBNI's Bioprin was featured in the Whole Dog Journal. Click the images to enlarge and read more!
Monday, September 1, 2008
JBNI Lung Cancer Early Detection and Biomarker Identification Technology
Background: Symptoms of lung cancer (LC) often do not appear until the disease is advanced; only 15% of LC cases are discovered while the tumor is in the early stages of development. Carcinogen exposure, asthma and smoking have been identified as risk factors for the development of LC. Early detection of LC will likely have a major impact on the natural history of the disease and facilitate curative treatment. The objective of the study was to apply mass spectrometric (MS) methods to identify a panel of biomarkers for early detection of LC.
Methods: Normal serum controls (NO; n = 30) from healthy volunteers and lung cancer patients (LC; n = 30) were acquired from a commercial vendor. Baseline pre-treatment) serum specimens from individuals with asthma (AST; n = 28) and lung cancer risk (LCR; n = 73) were available from clinical trials of two novel agents that are being developed by JBNI Inc. Serum proteins were analyzed using liquid chromatography electrospray ionization mass spectrometry (LC-ESIMS MS) to identify biomarkers that are expressed in a significantly different manner in individuals with LC, LCR, or AST in comparison with NO subjects. Specimens were digested with trypsin and analyzed by LC-ESIMS. Data were analyzed using Mascot search software.
Results: We have identified a number of heretofore unrecognized differentially expressed proteins in LC, LCR and AST samples relative to NO samples. The identified proteins include putative expressed proteins identified in prior genetic sequencing efforts, several patented proteins having functions that have not been described in the literature, a protein involved in intracytoplasmic protein membrane anchorage, a proteasome component, cellular immune response, as well as several MHC associated proteins.
Conclusions: Our results support an extended MS analysis of serum biomarker profiles as a supplementary tool in the identification of target molecules and systems for the subsequent application of quantitative validation techniques for the identification and molecular characterization of the condition and development of novel agents for prevention, early detection and treatment of LC.
Methods: Normal serum controls (NO; n = 30) from healthy volunteers and lung cancer patients (LC; n = 30) were acquired from a commercial vendor. Baseline pre-treatment) serum specimens from individuals with asthma (AST; n = 28) and lung cancer risk (LCR; n = 73) were available from clinical trials of two novel agents that are being developed by JBNI Inc. Serum proteins were analyzed using liquid chromatography electrospray ionization mass spectrometry (LC-ESIMS MS) to identify biomarkers that are expressed in a significantly different manner in individuals with LC, LCR, or AST in comparison with NO subjects. Specimens were digested with trypsin and analyzed by LC-ESIMS. Data were analyzed using Mascot search software.
Results: We have identified a number of heretofore unrecognized differentially expressed proteins in LC, LCR and AST samples relative to NO samples. The identified proteins include putative expressed proteins identified in prior genetic sequencing efforts, several patented proteins having functions that have not been described in the literature, a protein involved in intracytoplasmic protein membrane anchorage, a proteasome component, cellular immune response, as well as several MHC associated proteins.
Conclusions: Our results support an extended MS analysis of serum biomarker profiles as a supplementary tool in the identification of target molecules and systems for the subsequent application of quantitative validation techniques for the identification and molecular characterization of the condition and development of novel agents for prevention, early detection and treatment of LC.
Friday, August 15, 2008
Six Clove Korean Black Garlic
JBNI Releases Superfood: Immortal's Six Clove Black Garlic for Anti-Aging and Internal Vitality
Garlic has been a source of exponential vitality throughout history. But when common household garlic was scientifically tested, the results have been less than breathtaking. The Boston Globe published a report dated Feb 27, 2007 stating that 'garlic stinks for lowering cholesterol.'
“Health benefits have been thought to come from ... allicin,” The article continues, “'directly applied to cells has been shown to prevent cholesterol production. But any direct benefits to the body from allicin may be diluted when garlic is eaten,' said Gardner, an assistant professor of medicine at Stanford University.”
Scientific results like the above are not surprising. Over the centuries, across cultures and continents, allium sativum L. (common household garlic) has mistakenly taken the credit for its more powerful garlic cousins. Among these, the garlic species with the most healing properties is Korean Six Clove Black Garlic. JBNI has taken this genetically superior six clove garlic and further cultivated it using an ancient botanical process. This botanical process is a closely guarded secret among Korean Herbologists that yields the superfood: Immortal's Black Garlic.
Some of the mythical powers incorrectly attributed to common household garlic is the ability to reduce cholesterol, fight the flu, kill bacteria, restore vigorous male potency, fight tuberculosis, cancer, high blood pressure, and even is even being used to 'treat AIDS in an uncontrolled test done in China. One case where credit was mistakenly given to common garlic includes making the Israelites stronger than the Egyptians. This garlic diet apparently gave them the strength to build the pyramids. Others include epic battles involving Greek and Roman sailors who consumed garlic. This lead to legendary victories (See: Rawlinson's Herodotus and Virgil, Ecologues). And of course, garlic is purported to offer the power to ward off vampires.
This is not to say that common household garlic is altogether without merit. Even basic garlic was observed to demonstrate antibacterial activity by Louis Pasteur as far back as 1858. Later, garlic was used as an antiseptic to prevent gangrene during world wars I and II.
In any case, many mysterious powers were credited to common household garlic while it's truly potent cousin, alchemically cultivated 6 clove black garlic, quietly stood by out of the spot light.
JBNI invites athletes, tri-athletes, swimmers, cyclists, martial artists, runners, yoga instructors, and those who require increased internal power, stamina, and vitality to try Immortal's Black Garlic for 60 days to see for themselves whether these mythological claims are exaggerated or not.
Garlic has been a source of exponential vitality throughout history. But when common household garlic was scientifically tested, the results have been less than breathtaking. The Boston Globe published a report dated Feb 27, 2007 stating that 'garlic stinks for lowering cholesterol.'
“Health benefits have been thought to come from ... allicin,” The article continues, “'directly applied to cells has been shown to prevent cholesterol production. But any direct benefits to the body from allicin may be diluted when garlic is eaten,' said Gardner, an assistant professor of medicine at Stanford University.”
Scientific results like the above are not surprising. Over the centuries, across cultures and continents, allium sativum L. (common household garlic) has mistakenly taken the credit for its more powerful garlic cousins. Among these, the garlic species with the most healing properties is Korean Six Clove Black Garlic. JBNI has taken this genetically superior six clove garlic and further cultivated it using an ancient botanical process. This botanical process is a closely guarded secret among Korean Herbologists that yields the superfood: Immortal's Black Garlic.
Some of the mythical powers incorrectly attributed to common household garlic is the ability to reduce cholesterol, fight the flu, kill bacteria, restore vigorous male potency, fight tuberculosis, cancer, high blood pressure, and even is even being used to 'treat AIDS in an uncontrolled test done in China. One case where credit was mistakenly given to common garlic includes making the Israelites stronger than the Egyptians. This garlic diet apparently gave them the strength to build the pyramids. Others include epic battles involving Greek and Roman sailors who consumed garlic. This lead to legendary victories (See: Rawlinson's Herodotus and Virgil, Ecologues). And of course, garlic is purported to offer the power to ward off vampires.
This is not to say that common household garlic is altogether without merit. Even basic garlic was observed to demonstrate antibacterial activity by Louis Pasteur as far back as 1858. Later, garlic was used as an antiseptic to prevent gangrene during world wars I and II.
In any case, many mysterious powers were credited to common household garlic while it's truly potent cousin, alchemically cultivated 6 clove black garlic, quietly stood by out of the spot light.
JBNI invites athletes, tri-athletes, swimmers, cyclists, martial artists, runners, yoga instructors, and those who require increased internal power, stamina, and vitality to try Immortal's Black Garlic for 60 days to see for themselves whether these mythological claims are exaggerated or not.
Thursday, August 14, 2008
Vegan Pain Killer Options?
JBNI announced today their decision to focus on serving vegans and other groups who demand an all natural and 100% herbal complements to the synthetic pain killers already on the market. Although Bioprin has been on the market as a "physicians only" herbal formula since 1989, the focus of Bioprin had been to provide a formula for alleviating nervous system irritation and uncomfortable swelling. JBNI is now focusing on delivering this level of effectiveness to those to also wish to adhere to an herbal vegan diet.
“The formula has not changed," noted JBNI PR Representative. "How fast it works has not changed. How quickly Bioprin gets you to a point of nervous system comfort and ease has not changed. What has changed is that we are focusing on vegans because ironically, everyone but vegans seem to know about Bioprin.”
Alluding to published scientific documents, the JBNI representative continued, “Vegans are vegans because they are highly conscious of their health and the wellness of their bodies. They'll be happy to know that Bioprin has several benefits including healthy management of bacteria, mucus, fungus, swelling, and viruses.”
Bioprin has been documented to deliver effectiveness on several levels in addition to relieving discomfort and irritation. FPL (Food Products Laboratories) found that Bioprin destroys the H. Pylori Bacteria - a known cause of stomach ulcers and a Class 1 Carcinogen as deemed by the World Health Organization - on contact. 5,000,000 people are currently known to suffer from an ulcerated stomach lining. 1 in 10 people will experience an ulcer over their life time.
Bioprin has also been documented to demonstrate effectiveness against EMT-6 cells (human metastatic breast cancer cells) by Triple S Research Associates in connection with Dana Farber Cancer Institute/Harvard Medical School. Dr. Beverly Teicher's report states, “[Bioprin] is much more potent than Melphalan or Carmustine (commonly used chemotherapeutic agents), and comparable to radiotherapy.”
“There are no signs of toxicity with this herbal mixture," Dr. Teicher's report continues. "With the aid of radiotherapy, the result is highly enhanced to the level of 5.41 TGD [in days].”
For two decades, Bioprin has been offered by physicians to patients seeking relief from day to day discomfort and irritation caused by sports, repetitive motion, job related issues, emotional stress, or monthly women's issues. JBNI is now expanding their attention to serve vegans who seek Bioprin's level of effectiveness by adding another option to the synthetic pain killers already on the market.
“The formula has not changed," noted JBNI PR Representative. "How fast it works has not changed. How quickly Bioprin gets you to a point of nervous system comfort and ease has not changed. What has changed is that we are focusing on vegans because ironically, everyone but vegans seem to know about Bioprin.”
Alluding to published scientific documents, the JBNI representative continued, “Vegans are vegans because they are highly conscious of their health and the wellness of their bodies. They'll be happy to know that Bioprin has several benefits including healthy management of bacteria, mucus, fungus, swelling, and viruses.”
Bioprin has been documented to deliver effectiveness on several levels in addition to relieving discomfort and irritation. FPL (Food Products Laboratories) found that Bioprin destroys the H. Pylori Bacteria - a known cause of stomach ulcers and a Class 1 Carcinogen as deemed by the World Health Organization - on contact. 5,000,000 people are currently known to suffer from an ulcerated stomach lining. 1 in 10 people will experience an ulcer over their life time.
Bioprin has also been documented to demonstrate effectiveness against EMT-6 cells (human metastatic breast cancer cells) by Triple S Research Associates in connection with Dana Farber Cancer Institute/Harvard Medical School. Dr. Beverly Teicher's report states, “[Bioprin] is much more potent than Melphalan or Carmustine (commonly used chemotherapeutic agents), and comparable to radiotherapy.”
“There are no signs of toxicity with this herbal mixture," Dr. Teicher's report continues. "With the aid of radiotherapy, the result is highly enhanced to the level of 5.41 TGD [in days].”
For two decades, Bioprin has been offered by physicians to patients seeking relief from day to day discomfort and irritation caused by sports, repetitive motion, job related issues, emotional stress, or monthly women's issues. JBNI is now expanding their attention to serve vegans who seek Bioprin's level of effectiveness by adding another option to the synthetic pain killers already on the market.
Tuesday, August 5, 2008
JBNI Introduces Atmen for Allergies
JBNI, a recognized leader in the fields of cancer research, genetics, and proteomics, announced today the release of Atmen, an upper respiratory formula for allergies and sinus health. The release of this new formula was in response to JBNI users' demand for an upper respiratory formula for sinus allergies in addition to the already available Epstin. Epstin directly supports the immune system to alleviate general allergies and constant fatigue. It delivers vital energy by creating an immune system boost without any sudden rush or energy crash associated with popular energy drinks.
Epstin has been used by physicians and their patients to build up and support immune function while marginalizing intruders in order to help users become more vibrant and energetic. As a result of building their own internal immune system with Epstin's formula, allergens that were once an irritation rapidly become a non-issue. Atmen, like Epstin and all of JBNI's formulas including the Immortal's Anti-Aging Facial Soap, is made with 100% natural and herbal materials grown with no pesticides (with the exception of PiII which has synthetic parabens).
Complementing Epstin, which addresses constant fatigue, Atmen strictly focuses on sinus allergies impacting the upper respiratory system by supporting clear nasal breathing and sinus resilience. Atmen can benefit anyone suffering from allergies or those who work in environments where airborne dust and debris particle concentration is high.
When one of JBNI's research scientists was asked how Atmen works, he replied "The sinuses become inflamed and swell up under stress. This can either be caused by irritants, like pollen, or just plain overexertion. In either case, this inflammation causes headaches, restricted vision, problems with alertness, and everything else you can imagine would happen when you have restrictive tension in your head. Atmen helps to relieve this inflammation and swelling so that you can once again experience calm nasal respiration."
"Is Atmen safe?" one concerned user asked. "I mean, isn't the swelling of the sinus a normal bodily function? What happens when you stop that reaction from happening? Do I just breath in more garbage into my lungs?"
"All of JBNI's formulas are built on a strict health philosophy," JBNI's PR department responded. "We don't eliminate a symptom or even an undesirable bodily reaction. All of our formulas simply make the body stronger so it doesn't have to react. Atmen is the same way. It makes your sinuses more resilient so that your body doesn't have to react to stress."
JBNI General Manager Azim Walli welcomes inquiries regarding Atmen at http://jbni.us/account . JBNI is a long standing Seattle based company located in the exclusive biotech research community of Canyon Park, WA.
JBNI's Bioprin Demonstrates Anti-H. Pylori Results, A Known Cause of Stomach Ulcers
Warning: This document is intended for the scientific community only. Its sole purpose is to disclose test results concerning Bioprin, an herbal formula, as applied to H. Pylori.
SUMMARY: Due to a recent discovery by Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan that was published in the Lancet medical journal, JBNI has just released the anti-H. Pylori (a known cause of stomach ulcers) test report studying their herbal formula for nervous system health and comfort, Bioprin. This comes just after JBNI's last press release disclosing Bioprin's effectiveness on EMT-6, the equivalent of human metastatic breast cancer.
JBNI's Bioprin, their 100% herbal pain reliever, is reported to inhibit H. Pylori (a group I carcinogen for stomach cancer by the World Health Organization) in a clinical study by Food Products Laboratory, Inc. This study enlarges on the previous JBNI press release documenting Bioprin's anti-tumor effectiveness on EMT-6 (human metastatic breast cancer).
While only about 10,000 people die of stomach cancer annually, over 5,000,000 currently suffer from an ulcerated stomach lining, the main cause of stomach cancer. Over a lifetime, 1 in 10 will get a peptic ulcer which is, in turn, caused by H. Pylori.
Upon inhibition of H. Pylori, Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan demonstrated a two thirds lower likelihood of stomach cancer recurrence after initial treatment. To inhibit H. Pylori, Drs. Kato and Asaka used 30 milligrams of lansoprazole twice daily, 750 milligrams of amoxicillin twice daily, and 200 milligrams of clarithromycin twice a day for a week, Health Day news reported.
FPL's test of Bioprin against H. Pylori, FPL states, that Bioprin's testing "may indicate that H. Pylori is destroyed 100% on contact."
The summary impression states: "The inhibitor [Bioprin] is a highly turbid micro-granular natural herb extract. As the concentration increases, inhibition increases exponentially. This may indicate that H. Pylori is destroyed 100% on contact with the inhibitor. Very low inhibition by the clear supernatant of the formula supports this fact because the supernatant contains none or very little herbal extract. 10% supernatant results in 8mm inhibition zone. 10% whole Bioprin results in 30mm inhibition zone which is 10.56 times [greater] inhibition than the supernatant."
"MIC with well assays on TSA with 5% sheep blood" was the test method used. The spec as provided states, "well size: 6mm. Inhibition zones are the diameter including well."
When asked why Bioprin's anti-H. Pylori data was only recently published, Ken Case, JBNI's executive manager, stated, "JBNI wants to keep the message clear that Bioprin is first and foremost an all natural 100% herbal food supplement for nervous system calmness and vigor. It acts just as well to support the ease and comfort of muscles groups and vital organs that are under stress. Granted it tested high in anti-H. Pylori inhibition properties. Granted it shows anti-cancer properties reported by TSRA (Triple S Research Associates) in connection with Dana Farber Cancer Institute / Harvard Medical School. But JBNI's main focus for Bioprin is to safely and naturally deliver ease and comfort by supporting the body's own defense mechanisms."
Azim Walli, JBNI's general manager added, "Our entire line of herbal health formulas have multiple applications. But as with Bioprin, we want to focus on just one application so that the greatest number of people can experience the effectiveness of a purely herbal product. In fact, we don't even recommend that Bioprin be used in any other way than for aches and pains. We only share our test data with other scientists to educate on the potential of herbs."
Mr. Walli welcomes inquiry regarding distribution of JBNI's Bioprin at http://jbni.us/account . JBNI has been making the Bioprin formula broadly available to doctors and physicians for over 20 years. Bioprin has only been available directly to the public since July, 2008.
SUMMARY: Due to a recent discovery by Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan that was published in the Lancet medical journal, JBNI has just released the anti-H. Pylori (a known cause of stomach ulcers) test report studying their herbal formula for nervous system health and comfort, Bioprin. This comes just after JBNI's last press release disclosing Bioprin's effectiveness on EMT-6, the equivalent of human metastatic breast cancer.
JBNI's Bioprin, their 100% herbal pain reliever, is reported to inhibit H. Pylori (a group I carcinogen for stomach cancer by the World Health Organization) in a clinical study by Food Products Laboratory, Inc. This study enlarges on the previous JBNI press release documenting Bioprin's anti-tumor effectiveness on EMT-6 (human metastatic breast cancer).
While only about 10,000 people die of stomach cancer annually, over 5,000,000 currently suffer from an ulcerated stomach lining, the main cause of stomach cancer. Over a lifetime, 1 in 10 will get a peptic ulcer which is, in turn, caused by H. Pylori.
Upon inhibition of H. Pylori, Dr. Mototsugu Kato and Dr. Masahiro Asaka of Hokkaido University in Japan demonstrated a two thirds lower likelihood of stomach cancer recurrence after initial treatment. To inhibit H. Pylori, Drs. Kato and Asaka used 30 milligrams of lansoprazole twice daily, 750 milligrams of amoxicillin twice daily, and 200 milligrams of clarithromycin twice a day for a week, Health Day news reported.
FPL's test of Bioprin against H. Pylori, FPL states, that Bioprin's testing "may indicate that H. Pylori is destroyed 100% on contact."
The summary impression states: "The inhibitor [Bioprin] is a highly turbid micro-granular natural herb extract. As the concentration increases, inhibition increases exponentially. This may indicate that H. Pylori is destroyed 100% on contact with the inhibitor. Very low inhibition by the clear supernatant of the formula supports this fact because the supernatant contains none or very little herbal extract. 10% supernatant results in 8mm inhibition zone. 10% whole Bioprin results in 30mm inhibition zone which is 10.56 times [greater] inhibition than the supernatant."
"MIC with well assays on TSA with 5% sheep blood" was the test method used. The spec as provided states, "well size: 6mm. Inhibition zones are the diameter including well."
When asked why Bioprin's anti-H. Pylori data was only recently published, Ken Case, JBNI's executive manager, stated, "JBNI wants to keep the message clear that Bioprin is first and foremost an all natural 100% herbal food supplement for nervous system calmness and vigor. It acts just as well to support the ease and comfort of muscles groups and vital organs that are under stress. Granted it tested high in anti-H. Pylori inhibition properties. Granted it shows anti-cancer properties reported by TSRA (Triple S Research Associates) in connection with Dana Farber Cancer Institute / Harvard Medical School. But JBNI's main focus for Bioprin is to safely and naturally deliver ease and comfort by supporting the body's own defense mechanisms."
Azim Walli, JBNI's general manager added, "Our entire line of herbal health formulas have multiple applications. But as with Bioprin, we want to focus on just one application so that the greatest number of people can experience the effectiveness of a purely herbal product. In fact, we don't even recommend that Bioprin be used in any other way than for aches and pains. We only share our test data with other scientists to educate on the potential of herbs."
Mr. Walli welcomes inquiry regarding distribution of JBNI's Bioprin at http://jbni.us/account . JBNI has been making the Bioprin formula broadly available to doctors and physicians for over 20 years. Bioprin has only been available directly to the public since July, 2008.
Herbal Appetite Suppressant Released by JBNI, Leading Genetics and Proteomics Firm
In response to steady requests from physicians and the public over the last two decades, JBNI released a lip balm today that safely and immediately curbs appetite upon application. In keeping with JBNI's strict product development policy of using only 100% natural ingredients and no chemicals, the new JBNI appetite suppressant lip balm is another JBNI product with no known side effects or contraindications. As a result of a limited pre-release, feedback is already streaming in.
(August 3, 2008, Canyon Park, WA - PRWEB) Canyon Park, WA based JBNI, an internationally recognized genetics and cancer proteomics research firm just today publicly released their guarded 100% natural Appetite Suppressant Lip Balm. Today's decision is in response to over two decades of requests from physicians and the public. JBNI, satisfied with the long observation period, finally made the Appetite Suppressant Lip Balm, code named, "A.Balm," available to the general public.
Among the comments from the pre-release test group, Nancy Hokenson, a Registered Nurse relates, “Both my daughter and I had been using the lip balm for two weeks faithfully. It was time to do the weekly grocery shopping so off we went. We shopped and had our usual laughs etc. then it was check out time. The bill came up to half the amount as usual. I looked at her and asked if she hadn't gotten her usual for her house and I looked and it seemed like more than enough! I got back to the kitchen and noticed less extras and more basics, and there was even less of that! We called each other and said, 'Hey this lip balm really works!!!'”
After eight weeks, Nancy Hokenson's daughter has lost 50lbs.
Another user, Amy H., was asked by JBNI's marketing team to respond with a detailed explanation regarding how quickly the A.Balm works, how long it suppressed her appetite, and whether she experienced any loss of energy due to consuming less calories. She responded, “So far, it works!
JBNI's herbal product division which produces the A.Balm is Biodrux Corp. Biodrux is known to produce only 100% natural and herbal formulas tested by groups like the CTRC (Cancer Therapy and Research Center), TSRA (Triple S Research Associates) in connection with Dana Farber Cancer Institute / Harvard Medical School (see DFCI/HMS report on Bioprin), and IDD (Institute for Drug
Development). These prestigious scientific firms cite that Biodrux produces formulas that are as effective as commercially available alternatives. JBNI's market demanded a weight loss product that adhered to the same product efficacy standards.
When asked how it is possible to satisfy hunger cravings without any caloric intake, JBNI General Manager, Azim Walli, explained, "This is what our scientists told me: 'There is a dermal-visceral relationship between the lips and the stomach. Stimulation to the lips triggers a dialation response from the stomach making you feel hungry. The biochemistry of stomach expansion further lowers your blood sugar levels. In just about every culture, when mothers are trying to get their infants to feed, they instinctively tickle the lips. Babies open their mouths and begin to breast feed. This is a common understanding. A.Balm does exactly the opposite. It is an anti-stimulant that is herbal, safe, and causes no loss of sensitivity. This is how A.Balm either returns your stomach or keeps the stomach at the normal and healthy contracted state.'”
Mr. Azim Walli was further pressed by his early pre-release testers as to how a topical lip balm that acts so aggressively can be safe. His response explained that all of JBNI's products are not only 100% natural with no chemicals (with the exception of PiII which contains paraben), but they are all totally edible with zero toxicity levels. Even the herbs used by JBNI were grown with absolutely no pesticides.
Due to unexpectedly high pre-release demand for the new Biodrux Appetite Suppressant Lip Balm, Executive Manager Ken Case is rapidly ramping up production to satisfy the general public's demand.
Mr. Azim Walli can be reached for wholesale and distribution applications at http://JBNI.us/account and azimwalli@gmail.com. JBNI is located in the leading biotech center of Canyon Park, WA, and can be reached by phone at 425 408 9091.
(August 3, 2008, Canyon Park, WA - PRWEB) Canyon Park, WA based JBNI, an internationally recognized genetics and cancer proteomics research firm just today publicly released their guarded 100% natural Appetite Suppressant Lip Balm. Today's decision is in response to over two decades of requests from physicians and the public. JBNI, satisfied with the long observation period, finally made the Appetite Suppressant Lip Balm, code named, "A.Balm," available to the general public.
Among the comments from the pre-release test group, Nancy Hokenson, a Registered Nurse relates, “Both my daughter and I had been using the lip balm for two weeks faithfully. It was time to do the weekly grocery shopping so off we went. We shopped and had our usual laughs etc. then it was check out time. The bill came up to half the amount as usual. I looked at her and asked if she hadn't gotten her usual for her house and I looked and it seemed like more than enough! I got back to the kitchen and noticed less extras and more basics, and there was even less of that! We called each other and said, 'Hey this lip balm really works!!!'”
After eight weeks, Nancy Hokenson's daughter has lost 50lbs.
Another user, Amy H., was asked by JBNI's marketing team to respond with a detailed explanation regarding how quickly the A.Balm works, how long it suppressed her appetite, and whether she experienced any loss of energy due to consuming less calories. She responded, “So far, it works!
JBNI's herbal product division which produces the A.Balm is Biodrux Corp. Biodrux is known to produce only 100% natural and herbal formulas tested by groups like the CTRC (Cancer Therapy and Research Center), TSRA (Triple S Research Associates) in connection with Dana Farber Cancer Institute / Harvard Medical School (see DFCI/HMS report on Bioprin), and IDD (Institute for Drug
Development). These prestigious scientific firms cite that Biodrux produces formulas that are as effective as commercially available alternatives. JBNI's market demanded a weight loss product that adhered to the same product efficacy standards.
When asked how it is possible to satisfy hunger cravings without any caloric intake, JBNI General Manager, Azim Walli, explained, "This is what our scientists told me: 'There is a dermal-visceral relationship between the lips and the stomach. Stimulation to the lips triggers a dialation response from the stomach making you feel hungry. The biochemistry of stomach expansion further lowers your blood sugar levels. In just about every culture, when mothers are trying to get their infants to feed, they instinctively tickle the lips. Babies open their mouths and begin to breast feed. This is a common understanding. A.Balm does exactly the opposite. It is an anti-stimulant that is herbal, safe, and causes no loss of sensitivity. This is how A.Balm either returns your stomach or keeps the stomach at the normal and healthy contracted state.'”
Mr. Azim Walli was further pressed by his early pre-release testers as to how a topical lip balm that acts so aggressively can be safe. His response explained that all of JBNI's products are not only 100% natural with no chemicals (with the exception of PiII which contains paraben), but they are all totally edible with zero toxicity levels. Even the herbs used by JBNI were grown with absolutely no pesticides.
Due to unexpectedly high pre-release demand for the new Biodrux Appetite Suppressant Lip Balm, Executive Manager Ken Case is rapidly ramping up production to satisfy the general public's demand.
Mr. Azim Walli can be reached for wholesale and distribution applications at http://JBNI.us/account and azimwalli@gmail.com. JBNI is located in the leading biotech center of Canyon Park, WA, and can be reached by phone at 425 408 9091.
Monday, June 30, 2008
JBNI, Herbal Medicine, Genomics, and Biotechnology
Herbal medicines are considered health food in many Western nations. This perception is due to the slow action and low efficacy of herbal medicine.
JBNI scientists have formulated fast acting, safe, all-natural, food-grade, herbal remedies that are as effective as commercial pharmaceutical drugs. JBNI scientists have been developing naturaceuticals for decades.
In 1974, the scientists of JBNI (aka DHI) succeeded in developing all natural NSAID's (Non-Steroidal Anti-Inflammatory Drugs). While developing non-anaphylactic NSAIDs, they additionally succeeded in combining the strong anti-inflammatory function with anti-bacterial, anti-viral, anti-fungal, and anti-amoebic qualities by focusing on boosting the human immune function. As a result, the natural Formula 15.1 became the first anti-biotic which also eliminates fungal growth and is a powerful anti-inflammatory.
In 1978, JBNI (then OMR) scientists further succeeded in formulating over 50 natural internal and external remedies. These formulas have proven themselves to be as gentle as food while as effective as brand name pharmaceuticals.
In 1989, JBNI (then JJHC) succeeded in further improving Formula 15.1 by strengthening its anti-inflammatory action and pain killing capability by 400%. This improvement necessitated a new designation as Formula 15.3.
In 1991, JBNI (then JJI) scientists collaborated with TSRA (Triple S Research Associates) further improving the overall safety and efficacy. All of the oral formulas were raised to a new level of safety, beyond any government or public standard. Results achieved included yielding zero side effects with a single dose at 1/500 -1/100 of body weight. Many formulas were also tested against metastatic breast cancer (closely related to lung cancer), colorectal cancer, and skin cancer.
While JBNI and TSRA scientists were striving to set new industrial standards, they discovered that the FDA did not yet set any limitations on heavy metals in food products. FDA scientists developed new standards on heavy metal, herbicide, and pesticide content in the health food products due to data from TSRA and JBNI scientists.
In 1993, JBNI (aka JJI) began distributing nutritional health supplements exclusively to licensed physicians in the USA, including MDs, DOs, LAcs and DCs. This decision was implemented as part of a long-term clinical observation strategy.
Since 2001, JBNI (aka JJI) scientists intensified their research in the fields of genomics, genetics, DNA, proteomics and biomarkers. Together with IDD, CTRC, Beckman, Cyphergen, Luminex, Millipore, and Panomics, JBNI scientists succeeded in identifying biomarkers for forecasting many types of cancer decades before they strike. JBNI scientists, together with IDD, CTRC, and CPC, have been leading their peers in cancer prevention studies ever since. Abstracts documenting their
collaboration are featured annually in AACR, NIH, NCI, and EORTC conventions.
In 2004, JBNI's Azmazin received an IND (Investigational New Drug) number from the FDA as an asthma drug. It is expected to soon become the historic first oral and natural drug approved by the FDA. JBNI plans to further apply for drug approval for each of their products once Azmazin's approval process is finalized.
In 2007, JBNI, after three decades of carefully observed and private physician-only distribution, JBNI made select products available to the public. These products are sold as nutritional supplements with no claims. That same year, JBNI made these formulas available to the public online.
JBNI scientists have formulated fast acting, safe, all-natural, food-grade, herbal remedies that are as effective as commercial pharmaceutical drugs. JBNI scientists have been developing naturaceuticals for decades.
In 1974, the scientists of JBNI (aka DHI) succeeded in developing all natural NSAID's (Non-Steroidal Anti-Inflammatory Drugs). While developing non-anaphylactic NSAIDs, they additionally succeeded in combining the strong anti-inflammatory function with anti-bacterial, anti-viral, anti-fungal, and anti-amoebic qualities by focusing on boosting the human immune function. As a result, the natural Formula 15.1 became the first anti-biotic which also eliminates fungal growth and is a powerful anti-inflammatory.
In 1978, JBNI (then OMR) scientists further succeeded in formulating over 50 natural internal and external remedies. These formulas have proven themselves to be as gentle as food while as effective as brand name pharmaceuticals.
In 1989, JBNI (then JJHC) succeeded in further improving Formula 15.1 by strengthening its anti-inflammatory action and pain killing capability by 400%. This improvement necessitated a new designation as Formula 15.3.
In 1991, JBNI (then JJI) scientists collaborated with TSRA (Triple S Research Associates) further improving the overall safety and efficacy. All of the oral formulas were raised to a new level of safety, beyond any government or public standard. Results achieved included yielding zero side effects with a single dose at 1/500 -1/100 of body weight. Many formulas were also tested against metastatic breast cancer (closely related to lung cancer), colorectal cancer, and skin cancer.
While JBNI and TSRA scientists were striving to set new industrial standards, they discovered that the FDA did not yet set any limitations on heavy metals in food products. FDA scientists developed new standards on heavy metal, herbicide, and pesticide content in the health food products due to data from TSRA and JBNI scientists.
In 1993, JBNI (aka JJI) began distributing nutritional health supplements exclusively to licensed physicians in the USA, including MDs, DOs, LAcs and DCs. This decision was implemented as part of a long-term clinical observation strategy.
Since 2001, JBNI (aka JJI) scientists intensified their research in the fields of genomics, genetics, DNA, proteomics and biomarkers. Together with IDD, CTRC, Beckman, Cyphergen, Luminex, Millipore, and Panomics, JBNI scientists succeeded in identifying biomarkers for forecasting many types of cancer decades before they strike. JBNI scientists, together with IDD, CTRC, and CPC, have been leading their peers in cancer prevention studies ever since. Abstracts documenting their
collaboration are featured annually in AACR, NIH, NCI, and EORTC conventions.
In 2004, JBNI's Azmazin received an IND (Investigational New Drug) number from the FDA as an asthma drug. It is expected to soon become the historic first oral and natural drug approved by the FDA. JBNI plans to further apply for drug approval for each of their products once Azmazin's approval process is finalized.
In 2007, JBNI, after three decades of carefully observed and private physician-only distribution, JBNI made select products available to the public. These products are sold as nutritional supplements with no claims. That same year, JBNI made these formulas available to the public online.
Friday, June 27, 2008
Proteomic Biomarkers In Drug Development
Biomarker (noun): Biomarkers are cellular, biochemical, or molecular alterations that are measurable in biological media such as human tissues, cells, or fluids. They indicate the presence of biological events or concerted events that are directly associated with a particular disease state.
Molecular Biomarkers (noun): Molecular biomarkers include proteins, carbohydrates, nucleic acids, and other compounds that provide insight into an individual’s health for screening risk factors, diagnosis, and prognosis. Molecular biomarkers are also extremely useful for drug discovery purposes.
Clinical Needs, Patient Perspective:
Am I at risk for cancer?
Is there anything I can do to alter the risk?
Do I have cancer?
Will my cancer respond to therapy?
Is my cancer responding to therapy?
Clinical Needs, Physician Perspective:
Identification of fingerprints associated with:
Prognosis at the time of diagnosis
Tumor responsiveness to therapy
Inter- and intratumor heterogeneity
Metastatic potential
Disease progression
CONTINUED: See Full PDF Document: Proteomic Biomarkers In Drug Development
Conclusions:
The study demonstrated efficacy of IND#70190 with overall improved performance scores and alleviation of asthma symptoms
Novel protein biomarkers for asthma and drug efficacy were identified
Drug effects are consistent with potent anti-inflammatory activity of IND#70190
Further clinical development and investigation of drug mechanism of action is warranted
Molecular Biomarkers (noun): Molecular biomarkers include proteins, carbohydrates, nucleic acids, and other compounds that provide insight into an individual’s health for screening risk factors, diagnosis, and prognosis. Molecular biomarkers are also extremely useful for drug discovery purposes.
Clinical Needs, Patient Perspective:
Am I at risk for cancer?
Is there anything I can do to alter the risk?
Do I have cancer?
Will my cancer respond to therapy?
Is my cancer responding to therapy?
Clinical Needs, Physician Perspective:
Identification of fingerprints associated with:
Prognosis at the time of diagnosis
Tumor responsiveness to therapy
Inter- and intratumor heterogeneity
Metastatic potential
Disease progression
CONTINUED: See Full PDF Document: Proteomic Biomarkers In Drug Development
Conclusions:
The study demonstrated efficacy of IND#70190 with overall improved performance scores and alleviation of asthma symptoms
Novel protein biomarkers for asthma and drug efficacy were identified
Drug effects are consistent with potent anti-inflammatory activity of IND#70190
Further clinical development and investigation of drug mechanism of action is warranted
Novel serum biomarkers for renal cell carcinoma NIH AACR
Background: Renal cell carcinoma (RCC) is often undetected until it is in an advanced stage. Currently there are no reliable blood biomarkers to monitor 
the presence of the disease and/or response to therapies. Mass spectrometry (MS)-based proteomics provides tools for sensitive and high-throughput screening of proteinaceous biological samples and greatly facilitates biomarker iscovery.
Materials and methods: Sera from patients diagnosed with RCC were obtained at the baseline (n=14), then from the same individuals at 1 week (n=10), 2 weeks (n=5), and 3 weeks (n=7) after radical nephrectomy. In addition, unrelated RCC (n=4) and healthy control sera (n=30) were collected. Levels of inflammatory cytokines and growth factors (interleukins 1β, IL 2-7, 10, 12, and 13, GM-CSF, interferon-γ, TNF-α) were quantified in multiplex immunoassays. SELDI TOF MS protein profiling of the whole sera and specimens immunoprecipitated with anti-kallikrein antibodies was done in IMAC-Cu arrays. Further purification and identification of differentially expressed proteins was achieved by combination of two-dimensional gel electrophoresis (2DPAGE), in-gel trypsin digestion and LC-ESIMS for peptide fingerprinting. LC-ESIMS/MS was then used for de novo peptide sequence analysis. Mass spectral data were reduced using the Mascot database search engine. 
Initial matches were refined and confirmed against raw data and searched against decoy databases to reinforce identifications. Data were further refined using Progenesis Stats.
Results: Serum levels of all growth factors and cytokines (except IL-6) increased above the baseline until 3 weeks post-nephrectomy, with significant (p<0.05)>
Conclusions: SAA, an inflammatory acute phase protein, has been viewed as a biomarker of host response in many human cancers. The recently reported presence of SAA in tumor tissue suggests alternative function of the protein. Sudden disappearance of SAA versus persistent upregulation of multiple inflammatory proteins in post-nephrectomy RCC sera supports this notion. The additional matches derived from the 2D gels of the immunoprecipitates are all either reasonably expected or supported by recent literature identifications in other pathologies. The identifications of the other targets are being confirmed by independent methods. Selective proteome isolation by targeted MS is a promising analytical tool with potential clinical applications.
Identification of Serum Biomarkers for Lung Cancer
Background: Symptoms of lung cancer (LC) often do not appear until the disease is advanced; only 15% of LC cases are discovered while the tumor is in the early stages of development. Carcinogen 
exposure, asthma and smoking have been determined to be risk factors for the development of LC. Early detection of LC will likely have a major impact on the natural history of the disease and facilitate curative treatment. The objective of this study was to apply multiplexed immunoassays to identify a panel of biomarkers for early detection of LC.
Methods: Normal (NO) serum controls (n = 30) from healthy volunteers and lung cancer patients (n = 30) were acquired from a commercial vendor. Baseline (pre-treatment) serum specimens from individuals with asthma (AST; n = 28) and lung cancer risk (LCR; n = 73) were available from clinical trials of two novel agents that are being developed by JBNI Inc. for the respective indications. Serum levels of 59 cytokines, growth factors and biologically active peptides were quantified using multiplexed immunoassays using the Luminex platform to identify biomarkers that are expressed in a significantly different manner in individuals with LC, LCR, or AST in comparison with NO subjects. Data were reduced using nearest neighbor cluster analysis with squared Euclidian distance to separate patients into groups across analytes with inter-pathology comparisons determined using Student’s t test.
Results: Multiple analytes showed highly significant differences (p < 0.0002) between LC and healthy controls as single indices of pathologic state. In addition we were able to differentiate AST from LC (p < 0.002) and LCR and LC (p < 0.0001) using a panel of thirteen markers in various combinations. Using multiplexed assays we found significant differences in biomarker levels in sera of LC compared to NO, in NO compared to AST and LC compared to AST samples. Our results support an extended multiplexed immunoassay-based analysis of serum biomarker profiles as supplementary tools for the diagnosis of pathologic and as an aid in the development of novel agents for prevention, early detection and treatment of LC.
Conclusions: We have identified a group of markers having high inter-pathology discrimination power that are capable of reliably differentiating AST and LC from control specimens. This panel remains to be validated in a larger set of specimens but we are confident that these measures will produce clinical assays capable of reliably diagnosing lung pathology.
exposure, asthma and smoking have been determined to be risk factors for the development of LC. Early detection of LC will likely have a major impact on the natural history of the disease and facilitate curative treatment. The objective of this study was to apply multiplexed immunoassays to identify a panel of biomarkers for early detection of LC.Methods: Normal (NO) serum controls (n = 30) from healthy volunteers and lung cancer patients (n = 30) were acquired from a commercial vendor. Baseline (pre-treatment) serum specimens from individuals with asthma (AST; n = 28) and lung cancer risk (LCR; n = 73) were available from clinical trials of two novel agents that are being developed by JBNI Inc. for the respective indications. Serum levels of 59 cytokines, growth factors and biologically active peptides were quantified using multiplexed immunoassays using the Luminex platform to identify biomarkers that are expressed in a significantly different manner in individuals with LC, LCR, or AST in comparison with NO subjects. Data were reduced using nearest neighbor cluster analysis with squared Euclidian distance to separate patients into groups across analytes with inter-pathology comparisons determined using Student’s t test.
Results: Multiple analytes showed highly significant differences (p < 0.0002) between LC and healthy controls as single indices of pathologic state. In addition we were able to differentiate AST from LC (p < 0.002) and LCR and LC (p < 0.0001) using a panel of thirteen markers in various combinations. Using multiplexed assays we found significant differences in biomarker levels in sera of LC compared to NO, in NO compared to AST and LC compared to AST samples. Our results support an extended multiplexed immunoassay-based analysis of serum biomarker profiles as supplementary tools for the diagnosis of pathologic and as an aid in the development of novel agents for prevention, early detection and treatment of LC.Conclusions: We have identified a group of markers having high inter-pathology discrimination power that are capable of reliably differentiating AST and LC from control specimens. This panel remains to be validated in a larger set of specimens but we are confident that these measures will produce clinical assays capable of reliably diagnosing lung pathology.
16th EORTC-NCI-AACR Symposium on Molecular Targets, Cancer Therapeutics
28 September - 1 October 2004, Geneva, Switzerland
Abstracts
Abstract 583: Serum proteomic biomarkers of a natural product in a prospective randomized placebo-controlled clinical trial in patients at risk for lung cancer
Citation: European Journal of Cancer Supplements Volume 2, No.8, September 2004, page 177
S. Baek, D. Campos, E. Izbicka, J Jiang
Cancer Therapy and Research Center, The Institute for Drug Development, San Antonio, TX, USA
Smoking, asthma, and chronic obstructive pulmonary disease (COPD) are known risk factors for lung cancer. The disease may be preventable, but many potential chemopreventive agents have not shown clinical activity in individuals at risk for lung cancer (Van Zandvijk et al, Lung Cancer 2003, 42:S71). A novel natural product LP01 demonstrated preclinical preventive and anticancer activities, and induced time-and dose-dependent changes in serum kallikreins and proteomic patterns in human lung cancer xenograft models (Baek et al, Proc AACR/NCI/EORTC 2003).
The present study evaluated LP01 in a prospective, randomized, triple-masked, placebo-controlled, parallel-group clinical trial. In this study, lung cancer risk (15) was assessed based on length of addiction, asthma, and COPD, for a group of former long-term smokers (smoked >20 years, quit >1 year). This group, comprised of sixty men and women ages 3570, received oral daily doses of 3,650 mg LP01 or placebo for 6 months.
Peripheral blood serum specimens were obtained at the baseline and after drug treatment for 2 weeks, 1 month, 2 months, 4 and 6 months. Serum proteins were resolved on IMAC3/Cu metal affinity ProteinChip arrays and analyzed by surface-enhanced ligand desorption/ionization (SELDI). There were no adverse clinical effects of the therapy. The patients were stratified by the low risk (1 to -
Abstracts
Abstract 583: Serum proteomic biomarkers of a natural product in a prospective randomized placebo-controlled clinical trial in patients at risk for lung cancer
Citation: European Journal of Cancer Supplements Volume 2, No.8, September 2004, page 177
S. Baek, D. Campos, E. Izbicka, J Jiang
Cancer Therapy and Research Center, The Institute for Drug Development, San Antonio, TX, USA
Smoking, asthma, and chronic obstructive pulmonary disease (COPD) are known risk factors for lung cancer. The disease may be preventable, but many potential chemopreventive agents have not shown clinical activity in individuals at risk for lung cancer (Van Zandvijk et al, Lung Cancer 2003, 42:S71). A novel natural product LP01 demonstrated preclinical preventive and anticancer activities, and induced time-and dose-dependent changes in serum kallikreins and proteomic patterns in human lung cancer xenograft models (Baek et al, Proc AACR/NCI/EORTC 2003).
The present study evaluated LP01 in a prospective, randomized, triple-masked, placebo-controlled, parallel-group clinical trial. In this study, lung cancer risk (15) was assessed based on length of addiction, asthma, and COPD, for a group of former long-term smokers (smoked >20 years, quit >1 year). This group, comprised of sixty men and women ages 3570, received oral daily doses of 3,650 mg LP01 or placebo for 6 months.
Peripheral blood serum specimens were obtained at the baseline and after drug treatment for 2 weeks, 1 month, 2 months, 4 and 6 months. Serum proteins were resolved on IMAC3/Cu metal affinity ProteinChip arrays and analyzed by surface-enhanced ligand desorption/ionization (SELDI). There were no adverse clinical effects of the therapy. The patients were stratified by the low risk (1 to -
Subscribe to:
Posts (Atom)